Q3-osavuosiraportti
TänäänÄänite tulossa
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
11 000
Myynti
Määrä
133
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 133 | - | - | ||
| 8 000 | - | - | ||
| 5 000 | - | - | ||
| 6 965 | - | - | ||
| 3 517 | - | - |
Ylin
1,118VWAP
Alin
1,058VaihtoMäärä
0,4 346 864
VWAP
Ylin
1,118Alin
1,058VaihtoMäärä
0,4 346 864
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenWho is the new money? 1,07!!!!
·1 päivä sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.- ·1 päivä sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·1 päivä sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.
·1 päivä sittenThey do, however, surprisingly enough get their many emissions fully subscribed every time, so someone must believe in the case.·1 päivä sittenThat type of belief we have seen a lot of through many years, even at significantly higher issue prices. Faith can move mountains, it is said. But it apparently cannot change either the earnings or the direction of the share price chart, so, all the way, everyone just loses more and more money, all the time.- ·14.11.Stock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
- ·13.11.BioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html
·13.11.Good, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.
·14.11.Read the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
TänäänÄänite tulossa
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenWho is the new money? 1,07!!!!·1 päivä sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.
- ·1 päivä sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·1 päivä sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
- ·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.·1 päivä sittenThey do, however, surprisingly enough get their many emissions fully subscribed every time, so someone must believe in the case.·1 päivä sittenThat type of belief we have seen a lot of through many years, even at significantly higher issue prices. Faith can move mountains, it is said. But it apparently cannot change either the earnings or the direction of the share price chart, so, all the way, everyone just loses more and more money, all the time.
- ·14.11.Stock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
- ·13.11.BioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html·13.11.Good, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.·14.11.Read the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
11 000
Myynti
Määrä
133
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 133 | - | - | ||
| 8 000 | - | - | ||
| 5 000 | - | - | ||
| 6 965 | - | - | ||
| 3 517 | - | - |
Ylin
1,118VWAP
Alin
1,058VaihtoMäärä
0,4 346 864
VWAP
Ylin
1,118Alin
1,058VaihtoMäärä
0,4 346 864
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
TänäänÄänite tulossa
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. Tänään |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenWho is the new money? 1,07!!!!·1 päivä sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.
- ·1 päivä sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·1 päivä sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
- ·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.·1 päivä sittenThey do, however, surprisingly enough get their many emissions fully subscribed every time, so someone must believe in the case.·1 päivä sittenThat type of belief we have seen a lot of through many years, even at significantly higher issue prices. Faith can move mountains, it is said. But it apparently cannot change either the earnings or the direction of the share price chart, so, all the way, everyone just loses more and more money, all the time.
- ·14.11.Stock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
- ·13.11.BioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html·13.11.Good, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.·14.11.Read the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
11 000
Myynti
Määrä
133
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 133 | - | - | ||
| 8 000 | - | - | ||
| 5 000 | - | - | ||
| 6 965 | - | - | ||
| 3 517 | - | - |
Ylin
1,118VWAP
Alin
1,058VaihtoMäärä
0,4 346 864
VWAP
Ylin
1,118Alin
1,058VaihtoMäärä
0,4 346 864
Välittäjätilasto
Dataa ei löytynyt